138 related articles for article (PubMed ID: 27725294)
1. Aberrant expression of miR-9 in benign and malignant breast tumors.
Hasanzadeh A; Mesrian Tanha H; Ghaedi K; Madani M
Mol Cell Probes; 2016 Oct; 30(5):279-284. PubMed ID: 27725294
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of microRNA-19b in hormone receptor-positive/HER2-negative breast cancer.
Maleki E; Ghaedi K; Shahanipoor K; Karimi Kurdistani Z
APMIS; 2018 Apr; 126(4):303-308. PubMed ID: 29575198
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors.
Tahiri A; Leivonen SK; Lüders T; Steinfeld I; Ragle Aure M; Geisler J; Mäkelä R; Nord S; Riis ML; Yakhini Z; Kleivi Sahlberg K; Børresen-Dale AL; Perälä M; Bukholm IR; Kristensen VN
Carcinogenesis; 2014 Jan; 35(1):76-85. PubMed ID: 24104550
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of miRNA-9 and miRNA-34a as potential biomarkers for diagnosis of breast cancer in Iranian women.
Orangi E; Motovali-Bashi M
Gene; 2019 Mar; 687():272-279. PubMed ID: 30468908
[TBL] [Abstract][Full Text] [Related]
5. microRNA-214 enhances the invasion ability of breast cancer cells by targeting p53.
Wang F; Lv P; Liu X; Zhu M; Qiu X
Int J Mol Med; 2015 May; 35(5):1395-402. PubMed ID: 25738546
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
7. Analysis of serum genome-wide microRNAs for breast cancer detection.
Wu Q; Wang C; Lu Z; Guo L; Ge Q
Clin Chim Acta; 2012 Jul; 413(13-14):1058-65. PubMed ID: 22387599
[TBL] [Abstract][Full Text] [Related]
8. Role of miR-101 in pheochromocytoma patients with SDHD mutation.
Zong L; Meng L; Shi R
Int J Clin Exp Pathol; 2015; 8(2):1545-54. PubMed ID: 25973039
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker.
Erbes T; Hirschfeld M; Rücker G; Jaeger M; Boas J; Iborra S; Mayer S; Gitsch G; Stickeler E
BMC Cancer; 2015 Mar; 15():193. PubMed ID: 25886191
[TBL] [Abstract][Full Text] [Related]
10. Analysis of miRNA-221 Expression Level in Tumors and Marginal Biopsies from Patients with Breast Cancer (Cross-Sectional Observational Study).
Abak A; Amini S; Estiar MA; Montazeri V; Sakhinia E; Abhari A
Clin Lab; 2018 Jan; 64(1):169-175. PubMed ID: 29479893
[TBL] [Abstract][Full Text] [Related]
11. Decreased Expression of Bioinformatically Predicted piwil2-targetting microRNAs, miR-1267 and miR-2276 in Breast Cancer.
Torkashvand S; Damavandi Z; Mirzaei B; Tavallaei M; Vasei M; Mowla SJ
Arch Iran Med; 2016 Jun; 19(6):420-5. PubMed ID: 27293058
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of miRNAs that may be associated with the FHIT gene in breast cancer.
Sevinc ED; Cecener G; Ak S; Tunca B; Egeli U; Gokgoz S; Tolunay S; Tasdelen I
Gene; 2016 Sep; 590(2):278-84. PubMed ID: 27236032
[TBL] [Abstract][Full Text] [Related]
13. Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer.
Lu M; Ju S; Shen X; Wang X; Jing R; Yang C; Chu H; Cong H
Cancer Biomark; 2017; 18(2):143-148. PubMed ID: 27983524
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of miR-122, miR-574 and miR-375 in Egyptian patients with breast cancer.
Elghoroury EA; Abdelghafar EE; Kamel S; Awadallah E; Shalaby A; El-Saeed GSM; Mahmoud E; Kamel MM; Abobakr A; Yousef RN
PLoS One; 2024; 19(5):e0298536. PubMed ID: 38820252
[TBL] [Abstract][Full Text] [Related]
15. The role of upregulated miR-375 expression in breast cancer: An in vitro and in silico study.
Tang W; Li GS; Li JD; Pan WY; Shi Q; Xiong DD; Mo CH; Zeng JJ; Chen G; Feng ZB; Huang SN; Rong MH
Pathol Res Pract; 2020 Jan; 216(1):152754. PubMed ID: 31787478
[TBL] [Abstract][Full Text] [Related]
16. Expression and Tissue Distribution of MicroRNA-21 in Malignant and Benign Breast Tissues>.
Hug KA; Anthony L; Eldeiry D; Benson J; Wheeler E; Mousa S; Shi B
Anticancer Res; 2015 Jun; 35(6):3175-83. PubMed ID: 26026077
[TBL] [Abstract][Full Text] [Related]
17. Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.
Johannessen C; Moi L; Kiselev Y; Pedersen MI; Dalen SM; Braaten T; Busund LT
PLoS One; 2017; 12(10):e0186658. PubMed ID: 29073169
[TBL] [Abstract][Full Text] [Related]
18. Expression level of miR-93 in formalin-fixed paraffin-embedded tissues of breast cancer patients.
Deng ZQ; Qian J; Liu FQ; Lin J; Shao R; Yin JY; Tang Q; Zhang M; He L
Genet Test Mol Biomarkers; 2014 May; 18(5):366-70. PubMed ID: 24606013
[TBL] [Abstract][Full Text] [Related]
19. MiRNA expression analysis of cancer-associated fibroblasts and normal fibroblasts in breast cancer.
Zhao L; Sun Y; Hou Y; Peng Q; Wang L; Luo H; Tang X; Zeng Z; Liu M
Int J Biochem Cell Biol; 2012 Nov; 44(11):2051-9. PubMed ID: 22964023
[TBL] [Abstract][Full Text] [Related]
20. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
